Kurt von Emster

Kurt von Emster is an experienced professional in the life sciences investment sector, currently serving as Managing Partner and Head of Life Sciences at Abingworth since January 2015. In addition to this role, Kurt holds board positions at several pharmaceutical and biotechnology companies including Iambic Therapeutics, Tizona Therapeutics, Orbus Therapeutics, SFJ Pharmaceuticals, and Jasper Therapeutics. Previous board involvement includes CymaBay Therapeutics and leadership roles such as Chairman at Vaxcyte and Vera Therapeutics. Kurt von Emster holds a Bachelor of Science degree in Business and Economics from UC Santa Barbara, completed in 1989.